Citryll is developing CIT-013, a first-in-class monoclonal antibody that inhibits the formation of Neutrophil Extracellular Traps (NETs) and enhances their clearance, targeting a key mechanism in immune-mediated inflammatory diseases. The company focuses on treating conditions such as Rheumatoid Arthritis and Hidradenitis Suppurativa, where NETs contribute significantly to inflammation.
Funding
$127.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FCNVFounders
Product
Problem
Immune-mediated inflammatory diseases are driven by Neutrophil Extracellular Traps (NETs), a fundamental component of the inflammatory process that has been therapeutically unaddressed. Current treatments do not directly target NETs, leaving a critical mechanism of inflammation unchecked. This can lead to suboptimal outcomes for patients with conditions like Rheumatoid Arthritis and Hidradenitis Suppurativa.
Solution
Citryll is developing CIT-013, a first-in-class monoclonal antibody designed to inhibit the formation of NETs and enhance their clearance, thereby targeting a key driver of inflammation in immune-mediated diseases. CIT-013's unique dual mode of action offers a novel approach to treating these conditions by directly addressing the underlying inflammatory processes caused by NETs. By targeting NETs, Citryll aims to provide a more effective treatment option for patients suffering from Rheumatoid Arthritis, Hidradenitis Suppurativa, and other immune-mediated inflammatory disorders. This approach has the potential to transform the treatment landscape for these diseases.
Target Audience
The primary target audience includes patients suffering from immune-mediated inflammatory diseases such as Rheumatoid Arthritis and Hidradenitis Suppurativa, as well as the healthcare professionals who treat them.
Features
- First-in-class monoclonal antibody targeting NETs.
- Dual mode of action: inhibits NET formation and enhances NET clearance.
- Specifically designed to address the underlying inflammatory processes caused by NETs.
- Focus on treating Rheumatoid Arthritis and Hidradenitis Suppurativa.